350 rub
Journal Technologies of Living Systems №2 for 2014 г.
Article in number:
Tumor molecular markers in clinical oncology
Keywords: tumor molecular markers steroid hormone receptors growth factors growth factor receptors protein kinases tumor-associated proteases angiogenic markers microarrays
Authors:
N.E. Kushlinskii - Dr.Sc. (Med.), Professor, N.N. Blokhin Russian Cancer Research Center, Moscow
E.S. Gershtein - Dr.Sc. (Biol.), Professor, N.N. Blokhin Russian Cancer Research Center, Moscow
N.V. Lyubimova - Dr.Sc. (Biol.), Leading Research Scientist, N.N. Blokhin Russian Cancer Research Center, Moscow
Abstract:
The main biologically significant human tumor molecular markers (steroid hormone receptors, growth factors and downstream signaling proteins, tumor-associated proteases, angiogenic markers, biochemical markers of neuroendocrine tumors, bone metastases markers) are reviewed based on the background of contemporary literature and the results of long-term personal research. Methodic aspects, achievements of pre-clinical studies, and international recommendations on clinical implications of these parameters in disease prognosis and effective individualized treatment choice are represented. The recent data on the possibilities and pitfalls of the usage of modern high throughput technologies (microarrays) as an alternative to the determination of individual molecular markers are analyzed.
Pages: 3-18
References

  1. Gershtejn E.S., Androsova L.A., Letyagin V.P., Kushlinskij N.E. Klinicheskoe znachenie reczeptorov e'pidermal'nogo faktora rosta u bol'ny'x rasprostranenny'm rakom molochnoj zhelezy': rezul'taty' 6-letnego nablyudeniya // Vestnik Rossijskogo onkologicheskogo nauchnogo czentra im. N.N. Bloxina RAMN. 2000. № 1. S. 27-33.
  2. Gershtejn E.S., Bocharova L.B., Ermilova V.D. Reczeptory' e'pidermal'nogo faktora rosta i ix ligandy' v karczinomax e'ndometriya: svyaz' s kliniko-morfologicheskimi faktorami i reczeptorami steroidov. Voprosy' onkologii // Voprosy' onkologii. 2000. T. 46. № 2. S. 180-186.
  3. Gershtejn E.S., Griczaenko E.V., Shherbakov M.E. Faktor rosta e'ndoteliya sosudov i komponenty' sistemy' aktivaczii plazminogena pri rake i giperplazii e'ndometriya // Voprosy' onkologii. 2003. T. 49. № 6. S. 725-729.
  4. Gershtejn E.S., Korotkova E.A., Shherbakov A.M. Matriksny'e metalloproteinazy' 7 i 9 i ix tkanevy'e ingibitory' 1 i 4 tipa v opuxolyax i plazme krovi bol'ny'x rakom tolstoj kishki // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2007. T. 143. № 4. S. 438-441.
  5. Gershtejn E.S., Korotkova E.A., Prorokov V.V. Matriksny'e metalloproteinazy' 2, 3, 13 i ix tkanevoj ingibitor 2-go tipa v opuxolyax i plazme krovi bol'ny'x rakom tolstoj kishki // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2008. T. 145. № 3. S. 337-341.
  6. Gershtejn E.S., Kushlinskij N.E. Klinicheskie perspektivy' issledovaniya reczeptorov e'pidermal'nogo faktora rosta v opuxolyax cheloveka // Klinicheskaya laboratornaya diagnostika. 1996. № 1. C. 9-12.
  7. Gershtejn E.S., Kushlinskij N.E. Sovremenny'e predstavleniya o mexanizmax peredachi signalov faktorov rosta kak osnova e'ffektivnoj molekulyarno-napravlennoj protivoopuxolevoj terapii // Voprosy' biologicheskoj, mediczinskoj i farmaczevticheskoj ximii. 2007. № 1. S. 4-9.
  8. Gershtejn E.S., Kushlinskij N.E. Tkanevy'e markery' kak faktory' prognoza pri rake molochnoj zhelezy' / Prakticheskaya onkologiya: izbranny'e lekczii. Pod red. S.A. Tyulyandina i V.M. Moiseenko // «Centr TOMM». SPb. 2004. S. 41-50.
  9. Gershtejn E.S., Muaviya M.A., Kushlinskij N.E., Letyagin V.P. Prognosticheskoe znachenie opredeleniya reczeptorov e'pidermal'nogo faktora rosta u bol'ny'x rakom molochnoj zhelezy' I-II stadii: rezul'taty' shestiletnego nablyudeniya // Voprosy' onkologii. 1998. T. 44. № 4. S. 383-389.
  10. Gershtejn E.S., Talaeva Sh.Zh., Sandy'baev M.N., Kushlinskij N.E. Klinicheskaya rol' sistemy' aktivaczii plazminogena v opuxolyax cheloveka // Molekulyarnaya mediczina. 2007. № 1. S. 4-8.
  11. Gershtejn E.S., Shatskaya V.A., Laktionov K.K., Kushlinskij N.E., Krasil'nikov M.A. E'kspressiya fosfatidilinozitol-3 kinazy' pri rake legkogo // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2000. T. 130. № 12. S. 648-650.
  12. Gershtejn E.S., Shherbakov A.M., Alieva S.K. Faktor rosta e'ndoteliya sosudov v opuxolyax i sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy' // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2003. T. 135. № 1. S. 99-102.
  13. Gershtejn E.S., Shherbakov A.M., Goncharov D.Ju. Faktor rosta e'ndoteliya sosudov pri rake pishhevoda // Voprosy' biologicheskoj mediczinskoj i farmaczevticheskoj ximii. 2004. № 1. S. 26-29.
  14. Kim E.A, Gershtejn E.S., Vy'soczkaya I.V., Kushlinskij N.E. E'kspressiya VEGF i VEGFR2 v opuxolyax v proczesse neoad''yuvantnogo lecheniya bol'ny'x rakom molochnoj zhelezy' // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2008. T. 145. № 2. S. 206-209.
  15. Kim E.A., Gershtejn E.S., Shherbakov A.M., Vy'soczkaya I.V., Letyagin V.P., Kushlinskij N.E. Vliyanie neoad''yuvantnoj terapii na urovni VEGF i VEGFR-2 v opuxolyax i sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy' // Voprosy' onkologii. 2008. T. 54. № 3. S. 287-293.
  16. Kosty'leva O.I., Dy'xno A.Ju., Gershtejn E.S. Klinicheskoe i prognosticheskoe znachenie e'kspressii reczeptorov e'pidermal'nogo faktora rosta pri nemelkokletochnom rake legkogo // Byullyuten' e'ksperimental'noj biologii i medicziny'. 1999. T. 27. № 4. S. 446-449.
  17. Kosty'leva O.I., Radchenko A.A., Gershtejn E.S. Klinicheskoe znachenie reczeptorov e'pidermal'nogo faktora rosta i ix ligandov pri osteogennoj sarkome // Voprosy' biologicheskoj, mediczinskoj i farmaczevticheskoj ximii. 1998. № 1. S. 30-34.
  18. Kushlinskij N.E., Gershtejn E.S. Reczeptory' e'pidermal'nogo faktora rosta pri rake molochnoj zhelezy': ot e'ksperimenta k klinike // Byullyuten' e'ksperimental'noj biologii i medicziny'. 1998. T. 126. № 11. S. 485-496.
  19. Kushlinskij N.E., Gershtejn E.S. Rol' faktora rosta e'ndoteliya sosudov pri rake molochnoj zhelezy' // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2002. T. 133. № 6. S. 604-612.
  20. Kushlinskij N.E., Trapeznikova M.F., Gly'-bin P.A., Gershtejn E.S., Kazanczeva I.A., Ky'ly'chbekov M.B. Faktor rosta e'ndoteliya sosudov i ego reczeptor 2-go tipa v opuxolyax i sy'vorotke krovi bol'ny'x rakom pochki // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2008. T. 145. № 6. S. 691-694.
  21. Kushlinskij N.E., Shirokij V.P., Gershtejn E.S. Rastvorimy'j fragment reczeptora HER2/neu v sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy' s razny'm urovnem e'kspressii e'togo belka v opuxoli // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2007. T. 143. № 4. S. 427-430.
  22. Reczeptory' steroidny'x gormonov v opuxolyax cheloveka / pod red. L.S. Bassaly'k. M.: Mediczina. 1987. 223 s.
  23. Shherbakov A.M., Gershtejn E.S., Anurova O.A., Kushlinskij N.E. Aktivirovannaya proteinkinaza V pri rake molochnoj zhelezy' // Byullyuten' e'ksperimental'noj biologii i medicziny'. 2005. T. 139. № 5. S. 570-572.
  24. Shherbakov A.M., Gershtejn E.S., Anurova O.A., Kushlinskij N.E. Faktor rosta e'ndoteliya sosudov i ego reczeptory' pervogo i vtorogo tipa pri rake molochnoj zhelezy' // Voprosy' onkologii. 2005. T. 51. № 3. S. 317-321.
  25. De Laurentiis M., Cancello G., Zinno L., et al. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology // Ann. Oncol. 2005. V. 16. Suppl. 4. № iv7-iv13.
  26. Duffy M.J. Predictive markers in breast and other cancers: a review // Clinical Chemistry. 2005. V. 51. № 3. P. 494-503.
  27. Duffy M.J. Evidence for the clinical use of tumour markers // Ann. Clin. Biochem. 2004. V. 41. P. 370-377.
  28. Duffy M.J., Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer // Clin. Biochem. 2004. V. 37. P. 541-548.
  29. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer //N. Engl. J. Med. 2006. V. 355. № 6. P. 560-569.
  30. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors // Nat. Med. 2003. V. 9. № 6. P. 669-676.
  31. Gershtein E.S., Korotkova E.A., Prorokov V.V., Li Sini, Ryabov A.B., Kushlinsky N.E. Metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in tumors and plasma of gastric and colorectal cancer patients: relationship and clinico-pathologic implication / The 36th Meeting of the International Society of Oncology and BioMarkers, ISOBM-2008, Oct 5-9, 2008, Tokyo, Japan // Tumor Biology. 2008. V. 29. Suppl. 1. P. 63.
  32. Gershtein E.S., Scherbakov A.M., Anurova O.A., et al. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopa­thological features and tumor VEGF-signaling system component levels // Int. J. Biol. Markers. 2006. V. 21. P. 12-19.
  33. Gershtein E.S., Scherbakov A.M., Shatskaya V.A., et al. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinico-pathological correlations // Anticancer Research. 2007. V. 27. № 4A. P. 1777-1782.
  34. Gershtein E.S., Shatskaya V.A, Kushlinsky N.E. et al. Phosphatidylinositol 3-kinase expression in human breast cancer // Clin. Chim. Acta. - 1999. - Vol.287. - P. 59-67.
  35. Goldhirsch A., Glick J.H., Gelber R.D., et al. Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 // Ann. Oncol. 2005. V. 16. P. 1569-1583.
  36. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology // Endocr. Relat. Cancer. 2004. V. 11. № 4. P. 689-708.
  37. Ioannidis J.P. Gene expression profiling for individualized breast cancer chemotherapy: success or not - // Nat. Clin. Pract. Oncol. 2006. V. 3. № 10. P. 538-539.
  38. Janicke F., Prechtl A., Thomssen C., et al. For the German Chemo No Study Group. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 // J. Natl. Cancer Inst. 2001. V. 93. P. 913-920.
  39. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC // Int. J. Radiat. Oncol. Biol. Phys. 2004. V. 58. № 3. P. 991-1002.
  40. Li L. F., Xu X. J., Zhao Y., et al. Integrated gene expression profile predicts prognosis of breast cancer patients // Breast Cancer Res. Treat. 2009. V. 113. № 2. P. 231-237.
  41. Look M.P., van Putten W.L.J., Duffy M.J., et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients // J. Natl. Cancer Inst. 2002. V. 94. P. 116-128.
  42. Luftner D., Luke C., Possinger K. Serum HER-2/neu in the management of breast cancer patients // Clin. Biochem. 2003. V. 36. № 4. P. 233-240.
  43. Marchionni L., Wilson R.F., Wolff A. C., et al. Systematic review: gene expression profiling assays in early-stage breast cancer // Ann. Intern. Med. V. 148. № 5. P. 358-369.
  44. Modlich O., Prisack H.B., Bojar H. Breast cancer expression profiling: the impact of microarray testing on clinical decision making // Expert. Opin. Pharmacother. 2006. V. 7. № 15. P. 2069-2078.
  45. Moghal N., Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor // Curr. Opin. Cell Biol. 1999. V. 11. № 2. P. 190-196.
  46. Persing M. M., Paepke D., Schmidt M., et al. On behalf of the NNBC-3 Study Group. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 for improved management in node-negative (N0) breast cancer: Experiences from the ongoing multicenter trial NNBC 3-Europe / (ASCO Annual Meeting Proceedings. Post-Meeting Edition) // J. Clin. Oncol. 2007. V. 25. № 18 (Suppl.). P. 11081.
  47. Plosker G.L., Keam S.J. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer // Drugs. 2006. V. 66. № 4. P. 449-475.
  48. Pusztai L., Mazouni C., Anderson K., et al. Molecular classification of breast cancer: limitations and potential // Oncologist. 2006. V. 11. № 8. P. 868-877.
  49. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer - // Genet. Med. 2009. V. 11. № 1. P. 66-73.
  50. Reis-Filho J.S., Westbury C., Pierga J.Y. The impact of expression profiling on prognostic and predictive testing in breast cancer // J. Clin. Pathol. 2006. V. 59. № 3. P. 225-231.
  51. Rosell R., Taron M., Reguart N., et al. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway // Clin. Cancer Res. 2006. V. 12. № 24. P. 7222-7231.
  52. Ross J.S., Hatzis Ch., Symmans W.F., et al. Commercialized multigene predictors of clinical outcome for breast cancer // Oncologist. 2008. V. 13. № 5. P. 477-493.
  53. Roukos D.H., Paraskevaidis E., Kappas A.M. Surgery in the era of gene expression profiling-based prediction and individualized, neoadjuvant breast cancer therapy: the beginning of the end - // Ann. Surg. Oncol. 2006. V. 13. № 3. P. 433-435.
  54. Ryden L., Stendahl M., Jonsson H., et al. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response // Breast Cancer Res. Treat. 2005. V. 89. № 2. P. 135-143.
  55. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer // N. Engl. J. Med. 2009. V. 360. № 6. P. 563-572.
  56. Van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer // N. Engl. J. Med. 2002. V. 347. № 25. P. 1999-2009.
  57. Van Zandwijk N., Mathy A., Boerrigter L., et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer // Ann. Oncol. 2007. V. 18. № 1. P. 99-103.